Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Detalles Bibliográficos
Autores principales: Wenzel, Mike, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Briganti, Alberto, Mandel, Philipp, Montorsi, Francesco, Chun, Felix K. H., Karakiewicz, Pierre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638077/
https://www.ncbi.nlm.nih.gov/pubmed/36899091
http://dx.doi.org/10.1038/s41391-023-00656-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638077/
https://www.ncbi.nlm.nih.gov/pubmed/36899091
http://dx.doi.org/10.1038/s41391-023-00656-4

Ejemplares similares